Section 5 of 6
Economic information and modeling report
29 evidence topics · 13 sources
Modeling overview
Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence
No cost-effectiveness analysis, budget impact model, health technology assessment, or price of vonaprument (ANX007) was identified. ARCHER II, the phase 3 trial of monthly vonaprument 5.0 mg per eye versus sham in 659 participants, had a Data Monitoring Committee assessment of its Month 15 primary endpoint scheduled for the fourth quarter of 2026, so no product-specific efficacy input for a model was available. The manufacturer states that there is no assurance a product will be considered “cost-effective by third-party payors”. The comparator evidence consists of analyses of the two complement inhibitors approved in the United States, pegcetacoplan and avacincaptad pegol.
Two U.S. cost analyses based on 2022 Medicare reimbursement, estimated 2-year treatment costs of $70,000 (every month) and $34,600 (every other month) for pegcetacoplan, with modeled costs per QALY gained of $706,000 and $397,000, and 2-year costs of $67,400 (every month) and $40,600 (every other month) for avacincaptad pegol. For extrafoveal GA, the cost per mm2 of retinal pigment epithelium saved was higher with avacincaptad pegol than with pegcetacoplan for both dosing regimens ($119,000 vs $54,000 every month; $57,100 vs $31,400 every other month). A U.S. cost-utility model with authors from Apellis Pharmaceuticals, which included the costs and utility loss of informal caregiving, reported $77,735 per QALY gained over a lifetime horizon, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.
The Australian Pharmaceutical Benefits Advisory Committee (PBAC) assessed submissions for pegcetacoplan (November 2025) and avacincaptad pegol (March 2026). Each submission was a cost-utility analysis versus best supportive care with a 20-year time horizon; the pegcetacoplan model defined health states by ETDRS letter bands, and the avacincaptad pegol model by GA lesion size. For both products the PBAC stated that a price reduction would be required to achieve cost-effectiveness, and considered an ICER in the order of $55,000 to < $75,000 (pegcetacoplan) and $45,000 to < $55,000 (avacincaptad pegol) per QALY gained acceptable. For pegcetacoplan, the PBAC considered it reasonable to accept the financial estimates as the basis of a risk sharing arrangement. Should pegcetacoplan proceed to listing, the PBAC advised a cost-minimisation approach so that avacincaptad pegol was no more costly than pegcetacoplan. The NICE appraisal of pegcetacoplan was suspended after information the company provided in February 2025, which stated that it had not received MHRA marketing authorisation for the indication, and has since been discontinued.
Manufacturer statement on payer assessment of cost-effectiveness
Pegcetacoplan cost-effectiveness analysis: U.S. Medicare costs and cost per QALY
“Costs were based on 2022 Medicare reimbursement data. Specific outcomes were extrapolated from the DERBY and OAKS trials. Assumptions were made for the lifetime analysis based on a theoretical logistic growth model of the atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The costs to treat GA in every month (EM) and every-other-month (EOM) treatment groups over the 2 years as reported were $70 000 and $34 600, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The modeled lifetime costs were $350 000 (EM) and $172 000 (EOM), or $309 000/mm2 (EM) and $180 000 (EOM) /mm2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The costs/quality-adjusted life-year gained based on modeled visual loss with 95% atrophy were $706 000 (EM) and $397 000 (EOM).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment of GA with intravitreal pegcetacoplan EOM was more cost effective than EM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Avacincaptad pegol cost-effectiveness analysis: comparison with pegcetacoplan
“Costs were based on 2022 Medicare reimbursement data for both facility (hospital-based) and nonfacility settings in Miami.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost to treat GA with ACP in EM and EOM treatment groups over the 2 years as reported was $67 400 and $40 600, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The (facility-based) costs per unit area of retinal pigment epithelium saved for patients with extrafoveal GA over the 2-year period were $119 000/mm2 (EM ACP) versus $54 000/mm2 (EM PEG) (P < 0.001), $57 100/mm2 (EOM ACP) versus $31 400/mm2 (EOM PEG) (P < 0.001), and $45 300/mm2 (hypothetical EOM from outset ACP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When assessing extrafoveal lesions, ACP was less cost effective than PEG for both EM and EOM treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegcetacoplan de novo U.S. cost-utility model including informal caregiving
Australian PBAC assessment of pegcetacoplan: model structure and ICER
Australian PBAC assessment of avacincaptad pegol: model structure, ICER, and cost-minimisation with pegcetacoplan
NICE appraisal of pegcetacoplan: suspension and discontinuation
Budget impact model
Approach and framework
Budget impact model of vonaprument
No evidence found.
Pegcetacoplan PBAC financial estimates: epidemiological approach
Avacincaptad pegol PBAC financial estimates: epidemiological approach and market share
Perspective and time frame
Budget impact model of vonaprument: perspective and time frame
No evidence found.
Pegcetacoplan PBAC financial estimates: payer perspective and 6-year horizon
Avacincaptad pegol PBAC financial estimates: population projections, 2027 to 2032
Epidemiology and eligible population inputs
Budget impact model of vonaprument: eligible population
No evidence found.
Company estimate of the U.S. treated and diagnosed GA population
Company estimate of GA prevalence in the United States and worldwide
Pegcetacoplan PBAC financial estimates: prevalence, eligibility, and uptake inputs
Avacincaptad pegol PBAC financial estimates: incidence, prevalence, and non-subfoveal proportion
Cost assumptions
Price of vonaprument
No evidence found.
Vonaprument dose and frequency in ARCHER II
Medicare Part B payment limits for comparator complement inhibitors, October to December 2026
| HCPCS code and product | Short description | Billing unit | Payment limit per billing unit (dollars) | Notes |
|---|---|---|---|---|
| J2781 pegcetacoplan (Syfovre) | “Inj, pegcetacoplan, 1mg” | “1 MG” | “135.267” | “AMP-based payment limit” |
| J2782 avacincaptad pegol (Izervay) | “Inj avacincaptad pegol 0.1mg” | “0.1 MG” | “100.563” | Not reported |
Medicare Part B spending and beneficiaries for comparator complement inhibitors, 2023 and 2024
| HCPCS code and product | Total spending, 2023 (dollars) | Total beneficiaries, 2023 | Total spending, 2024 (dollars) | Total claims, 2024 | Total beneficiaries, 2024 | Average spending per claim, 2024 (dollars) | Average spending per beneficiary, 2024 (dollars) |
|---|---|---|---|---|---|---|---|
| J2781 pegcetacoplan (Syfovre) | “76651580.03” | “17414” | “403855394.8” | “148576” | “29338” | “2718.173829” | “13765.60757” |
| J2782 avacincaptad pegol (Izervay) | Not reported | Not reported | “190365232.8” | “73172” | “18308” | “2601.613086” | “10397.92619” |
Medicare Part B quarterly spending and beneficiaries for comparator complement inhibitors, 2025 and first quarter of 2026
| HCPCS code and product | Period | Total spending (dollars) | Total claims | Total beneficiaries | Average spending per claim (dollars) | Average spending per beneficiary (dollars) |
|---|---|---|---|---|---|---|
| J2781 pegcetacoplan (Syfovre) | “2025 (Q1-Q4)” | “451069360.05” | “168366” | “32021” | “2679.1000561” | “14086.673122” |
| J2781 pegcetacoplan (Syfovre) | “2026 (Q1)” | “109568082.68” | “41654” | “24179” | “2630.4336361” | “4531.5390496” |
| J2782 avacincaptad pegol (Izervay) | “2025 (Q1-Q4)” | “364934587.1” | “140741” | “27497” | “2592.9515003” | “13271.796454” |
| J2782 avacincaptad pegol (Izervay) | “2026 (Q1)” | “105232261.84” | “41264” | “23315” | “2550.2196064” | “4513.5004006” |
Launch wholesale acquisition costs of comparator complement inhibitors, 2023
Comparator dosing frequency assumed in PBAC financial estimates
Model outcomes
Budget impact model of vonaprument: outcomes
No evidence found.
Avacincaptad pegol PBAC financial estimates: outcomes reported
“Number of patients treated” (opens the source at this quote in a new tab)
“Patient-years on treatment” (opens the source at this quote in a new tab)
“Number of scripts dispensed” (opens the source at this quote in a new tab)
“Net cost to PBS/RPBS” (opens the source at this quote in a new tab)
“Net cost to MBS” (opens the source at this quote in a new tab)
Results
Base case
Budget impact model of vonaprument: base case
No evidence found.
Avacincaptad pegol PBAC financial estimates: base case
Scenario analyses
Budget impact model of vonaprument: scenario analyses
No evidence found.
Avacincaptad pegol PBAC financial estimates: continued monthly dosing after year 1
Pegcetacoplan PBAC financial estimates: revisions to scripts and uptake
Budget impact model discussion
Summary: inputs a vonaprument budget impact model would require
No budget impact model of vonaprument exists. A U.S. payer model would require four inputs that are not yet available: a price (none announced), efficacy and discontinuation data from ARCHER II, the labeled dosing frequency (ARCHER II tests monthly vonaprument 5.0 mg per eye), and the eligible population defined by an approved indication.
Comparator inputs exist for the two complement inhibitors already approved in the United States. October to December 2026 Medicare Part B payment limits were $135.267 per 1 mg of pegcetacoplan (J2781, an AMP-based payment limit) and $100.563 per 0.1 mg of avacincaptad pegol (J2782); launch list prices in 2023 were $2,190 and $2,100 per vial. Medicare Part B spending in 2025 was $451.1 million for Syfovre (32,021 beneficiaries; $2,679 per claim) and $364.9 million for Izervay (27,497 beneficiaries; $2,593 per claim), compared with $403.9 million (29,338 beneficiaries) and $190.4 million (18,308 beneficiaries) in 2024. The 2026 national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23. The manufacturer estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 diagnosed with GA or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. patients with GA.
The two Australian PBAC financial estimates illustrate the structure such a model would take: an epidemiological approach, a prevalence of 1.29% (pegcetacoplan, aged 60 years and older) or 0.52% (avacincaptad pegol, aged 50 years and older), the proportion with non-subfoveal GA (31.60% for avacincaptad pegol), an uptake curve, injections per year, and administration costs, over 6 years. Both estimates were sensitive to dosing frequency: the PBAC revised pegcetacoplan from 4.5 to 5.39 scripts per year, and for avacincaptad pegol the evaluation tested scenarios in which 50% or 100% of patients continued monthly dosing after year 1, after which the estimated year 6 cost was $70 million to < $80 million, compared with $60 million to < $70 million in the submission. The evaluation of avacincaptad pegol stated that market share calculations would be necessary if pegcetacoplan were listed, a consideration that would also apply to a third agent.